^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr del(17p)

    Related tests:
    6d
    ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Chr del(17p)
    |
    cyclophosphamide • fludarabine IV
    14d
    Application of the New IMWG/IMS High-Risk Classification for Multiple Myeloma: Analysis of a Large Real-World Romanian Cohort. (PubMed, Int J Mol Sci)
    Despite high response rates achieved with modern therapies, survival remains inferior in HR patients. TANDEM ASCT did not confer additional benefit in this cohort, supporting a more individualized approach to treatment intensification.
    Retrospective data • Journal • Real-world evidence
    |
    TP53 (Tumor protein P53)
    |
    Chr del(17p)
    24d
    TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition. (PubMed, Sci Adv)
    Chemical screening identified HSP90 inhibition as a selective vulnerability in AML with low RPG expression. These findings highlight a previously unappreciated TP53-altered AML subset characterized by converging genomic and translational defects and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.
    Journal
    |
    TP53 (Tumor protein P53) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    TP53 mutation • Chr del(17p) • Chr del(5q)
    3ms
    ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=19, Completed, Ciusss de L'Est de l'Île de Montréal | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    CD34 (CD34 molecule)
    |
    Chr del(17p)
    |
    cyclophosphamide • melphalan • Zemcelpro (dorocubicel)
    3ms
    GFH009X2101: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Sellas Life Sciences Group | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • DDX41 (DEAD-Box Helicase 41) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TP53 mutation • KRAS mutation • FLT3-ITD mutation • Chr del(17p) • IDH1 mutation • IDH2 mutation • FLT3 mutation • TP53 wild-type • NPM1 mutation • KRAS wild-type • Chr del(11q) • ASXL1 mutation • SF3B1 mutation • EZH2 mutation • NRAS wild-type • SRSF2 mutation • IDH wild-type
    |
    Venclexta (venetoclax) • azacitidine • tambiciclib (SLS009)
    4ms
    CAR BCMA-70 CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Affiliated Hospital to Academy of Military Medical Sciences
    New P1 trial
    |
    TP53 (Tumor protein P53) • CD70 (CD70 Molecule)
    |
    TP53 mutation • Chr del(17p)
    |
    cyclophosphamide • fludarabine IV
    4ms
    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2028 | Initiation date: Jan 2026 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Chr del(17p)
    |
    clonoSEQ®
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    4ms
    Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis. (PubMed, Cytometry A)
    This pilot study demonstrates that imaging flow cytometry-based FISH of circulating CD34/CD45-positive cells enables real-time, blood-based surveillance for cytogenetic evolution in myelofibrosis. The ability to dynamically track clone size and hierarchy highlights its potential as an early predictor of leukemic transformation in myelofibrosis.
    Journal
    |
    CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    Chr del(17p) • Chr del(5q)
    4ms
    Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial (clinicaltrials.gov)
    P1/2, N=27, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A deletion
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    6ms
    Efficacy of melflufen in multiple myeloma with mutated or deleted TP53. (PubMed, Exp Hematol Oncol)
    Post-hoc analysis of the OCEAN trial melflufen-treated del(17p) patient population also demonstrated favorable progression free survival compared to pomalidomide-treated cohort. Our insights into the molecular mechanisms of melflufen activity in TP53-/- myeloma support its clinical efficacy and application in the del(17p) and TP53-/- patient population.Trial registration NCT03151811, registration 2017-05-09.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion
    |
    pomalidomide • Melflufen (melphalan flufenamide)
    6ms
    P17-132: Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, AbbVie | Active, not recruiting --> Recruiting | N=350 --> 500 | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2030
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)
    |
    Venclexta (venetoclax)
    6ms
    ASSURE: Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov)
    P3, N=552, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)